Dexamethasone 4 mg Tablet, 15-count
🆔 Identity & classification
Where does this data come from?
🏷️ RxNorm drug class
This medicine belongs to the Corticosteroid class.
Where does this data come from?
🏭 Manufacturer & labeler
Where does this data come from?
🩺 Clinical
Dexamethasone, a corticosteroid, is similar to a natural hormone produced by your adrenal glands. It often is used to replace this chemical when your body does not make enough of it. It relieves inflammation (swelling, heat, redness, and pain) and is used to treat certain forms of arthritis; skin, blood, kidney, eye, thyroid, and intestinal disorders (e.g., colitis); severe allergies; and asthma. Dexamethasone is also used to treat certain types of cancer. This medication is sometimes prescribed for other uses; ask your doctor or pharmacist for more information.
Read the full MedlinePlus article ↗- You're right that it treats a lot of conditions, and that can feel confusing. Dexamethasone is a corticosteroid, which is a type of anti-inflammatory medicine. Whether it's calming...
- Why has my doctor prescribed dexamethasone — it seems to be used for so many different things?
- Please don't stop it abruptly without talking to your doctor first, especially if you've been on it for more than a few days. Your body adjusts to having this medication on board,...
- Can I just stop taking dexamethasone if I feel better or if I'm worried about side effects?
Patient education
Supplement & herbal interactions
Some supplements/herbs that may interact with Dexamethasone — tap one for details:
Dexamethasone may be associated with lower levels of 8 nutrients — worth a chat with your pharmacist, not a cause for alarm.
Where does this data come from?
Ask a licensed pharmacist directly — free, answered by our team.
💊 What it looks like
Where does this data come from?
🧪 Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII 35SW5USQ3G
A synthetic yellow dye used to color medicines. It helps make tablets, capsules, and liquids visually distinct so patients can easily identify their medication.
-
UNII EWQ57Q8I5X
Lactose monohydrate is a natural sugar derived from milk. It serves as a filler and binder in tablets and capsules, helping create the proper size, texture, and consistency of the medicine.
-
UNII 70097M6I30
Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
-
UNII O8232NY3SJ
A plant-based carbohydrate derived from corn kernels. It acts as a filler to add bulk, a binder to hold ingredients together, and a disintegrant to help the tablet break apart in your stomach for absorption.
4 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
💲 Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per each | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · Q2 2026 | $0.0986 | $1.48 / 15 tablets |
Where does this data come from?
🔁 Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Dexamethasone 4 mg 00054-4184-25 | Hikma | 100 tablets | $0.188 | AB | Availability likely | — |
| Dexamethasone 4 mg 00054-8175-25 | Hikma | 100 tablets | $0.188 | AB | Availability likely | — |
| dexamethasone 4 mg 00904-7266-61 | Major | 100 tablets | $0.188 | AB | Availability likely | — |
| Dexamethasone 4 mg 47781-0914-01 | Alvogen | 100 tablets | $0.188 | BP | Availability likely | — |
| dexamethasone 4 mg 60219-2043-01 | Amneal | 100 tablets | $0.188 | AB | Availability likely | — |
| Dexamethasone 4 mg 60505-6254-01 | Apotex | 100 tablets | $0.188 | AB | Availability likely | — |
| Dexamethasone 4 mg 60687-0718-01 | American | 100 tablets | $0.188 | AB | Availability likely | — |
| Dexamethasone 4 mg 66993-0730-02 | Prasco | 100 tablets | $0.188 | — | Availability likely | — |
| Dexamethasone 4 mg 69452-0277-20 | Bionpharma | 100 tablets | $0.188 | AB | Availability likely | — |
| Dexamethasone 4 mg 70954-0403-10 | ANI | 100 tablets | $0.188 | AB | Availability likely | — |
| Dexamethasone 4 mg 72578-0171-01 | Viona | 100 tablets | $0.188 | AB | Availability likely | — |
| Dexamethasone 4 mg 72603-0189-01 | NorthStar | 100 tablets | $0.188 | AB | Availability likely | — |
| Dexamethasone 4 mg 72888-0240-01 | Advagen | 100 tablets | $0.188 | AB | Availability likely | — |
| Dexamethasone 4 mg 50090-6151-04 | A-S | 6 tablets | — | — | FDA listed | — |
| Dexamethasone 4 mg 50090-6152-00 | A-S | 28 tablets | — | — | FDA listed | — |
| Dexamethasone 4 mg 51407-0361-01 | Golden | 100 tablets | — | AB | FDA listed | — |
| Dexamethasone 4 mg 51655-0012-03 | Northwind | 3 tablets | — | AB | FDA listed | — |
| dexamethasone 4 mg 55154-4315-00 | Cardinal | 10 tablets | — | AB | FDA listed | — |
| Dexamethasone 4 mg 55154-4901-00 | Cardinal | 10 tablets | — | AB | FDA listed | — |
| Dexamethasone 4 mg 55289-0582-04 | PD-Rx | 4 tablets | — | AB | FDA listed | — |
| Dexamethasone 4 mg 63187-0561-00 | Proficient | 100 tablets | — | AB | FDA listed | — |
| Dexamethasone 4 mg 63629-3742-00 | Bryant | 4 tablets | — | AB | FDA listed | — |
| Dexamethasone 4 mg 67296-1837-01 | Redpharm | 10 tablets | — | BP | Discontinued | — |
| Dexamethasone 4 mg 68071-3588-01 | NuCare | 10 tablets | — | AB | FDA listed | — |
| Dexamethasone 4 mg 68071-3603-08 | NuCare | 8 tablets | — | AB | FDA listed | — |
| Dexamethasone 4 mg 68788-4113-01 | Preferred | 12 tablets | — | AB | FDA listed | — |
| Dexamethasone 4 mg 68788-8467-01 | Preferred | 12 tablets | — | AB | FDA listed | — |
| Dexamethasone 4 mgthis 68788-8824-05 | Preferred | 15 tablets | — | AB | FDA listed | — |
| Dexamethasone 4 mg 69306-0114-06 | Doc | 6 tablets | — | AB | FDA listed | — |
| Dexamethasone 4 mg 70518-1534-00 | REMEDYREPACK | 30 tablets | — | AB | FDA listed | — |
| Dexamethasone 4 mg 70518-4320-00 | REMEDYREPACK | 4 tablets | — | AB | FDA listed | — |
| Dexamethasone 4 mg 70771-1699-01 | Zydus | 100 tablets | — | AB | FDA listed | — |
| Dexamethasone 4 mg 71205-0703-20 | Proficient | 20 tablets | — | BP | FDA listed | — |
| Dexamethasone 4 mg 71335-2108-00 | Bryant | 4 tablets | — | BP | FDA listed | — |
| Dexamethasone 4 mg 71335-2227-00 | Bryant | 4 tablets | — | AB | FDA listed | — |
| Dexamethasone 4 mg 71335-2500-00 | Bryant | 4 tablets | — | AB | FDA listed | — |
| Dexamethasone 4 mg 71335-3054-00 | Bryant | 4 tablets | — | AB | FDA listed | — |
| Dexamethasone 4 mg 72189-0254-10 | Direct | 10 tablets | — | AB | FDA listed | — |
| Dexamethasone 4 mg 72189-0511-10 | Direct_Rx | 10 tablets | — | AB | FDA listed | — |
| Dexamethasone 4 mg 72789-0534-01 | PD-Rx | 100 tablets | — | AB | FDA listed | — |
| Dexamethasone 4 mg 80425-0328-01 | Advanced | 12 tablets | — | BP | FDA listed | — |
| Dexamethasone 4 mg 80425-0515-01 | Advanced | 12 tablets | — | AB | FDA listed | — |
| Dexamethasone 4 mg 82804-0157-04 | Proficient | 4 tablets | — | AB | FDA listed | — |
| Dexamethasone 4 mg 82804-0254-15 | Proficient | 15 tablets | — | AB | FDA listed | — |
| Dexamethasone 4 mg 85766-0246-01 | Sportpharm | 100 tablets | — | AB | FDA listed | — |
Where does this data come from?
⏳ Availability & generic status
This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.
Where does this data come from?
📊 Medicare Part D spend CMS · PART D · 2026 (Q1)
🔬 Reported adverse events (FAERS)
Top reported reactions
Age at onset
Reporter sex
Serious outcomes
Where does this data come from?
📦 Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Status |
|---|---|---|---|
| 68788-8824-01 | 12 TABLET in 1 BOTTLE (68788-8824-1) | 2025-02-10 | Active |
| 68788-8824-03 | 30 TABLET in 1 BOTTLE (68788-8824-3) | 2025-02-10 | Active |
| 68788-8824-05 You're viewing this | 15 TABLET in 1 BOTTLE (68788-8824-5) | 2025-02-10 | Active |
| 68788-8824-06 | 6 TABLET in 1 BOTTLE (68788-8824-6) | 2025-02-10 | Active |
You're viewing one of 4 pack sizes for this product.
Pack size FAQ
What quantity is in NDC 68788-8824-05?
What is the difference between NDC 68788-8824-05 and NDC 68788-8824-06?
What NDC number is used to bill for this package of Dexamethasone 4 mg Tablet?
🧭 About this NDC listing & data coverage
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | ✓ Available |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | ✓ Available |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |
Questions about this listing
Why is there no price listed?
Is the NDC printed on the package the same as the 11-digit billing NDC?
What do the three segments of this NDC mean?
Is this package still being marketed?
Does this product come in other package sizes?
Who lists this product with the FDA?
Do I need a prescription for this product?
Where does this data come from?
📄 Full prescribing information FDA SPL
🎯 Indications and Usage ▾
INDICATIONS AND USAGE Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis.
Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous: Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy.
Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.
Renal diseases: To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy).
For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.
⏱️ Dosage and Administration ▾
DOSAGE AND ADMINISTRATION For Oral Administration The initial dosage varies from 0.75 mg to 9 mg a day depending on the disease being treated. It Should Be Emphasized That Dosage Requirements Are Variable and Must Be Individualized on The Basis of The Disease Under Treatment and The Response of The Patient. After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage that maintains an adequate clinical response is reached.
Situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient's individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment. In this latter situation it may be necessary to increase the dosage of the corticosteroid for a period of time consistent with the patient's condition. If after long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly.
In the treatment of acute exacerbations of multiple sclerosis, daily doses of 30 mg of dexamethasone for a week followed by 4 mg to 12 mg every other day for one month have been shown to be effective (see PRECAUTIONS , Neuro-psychiatric ). In pediatric patients, the initial dose of dexamethasone may vary depending on the specific disease entity being treated. The range of initial doses is 0.02 mg/kg/day to 0.3 mg/kg/day in three or four divided doses (0.6 mg/m 2 bsa/day to 9 mg/m 2 bsa/day).
For the purpose of comparison, the following is the equivalent milligram dosage of the various corticosteroids: Cortisone, 25 mg Triamcinolone, 4 mg Hydrocortisone, 20 mg Paramethasone, 2 mg Prednisolone, 5 mg Betamethasone, 0.75 mg Prednisone, 5 mg Dexamethasone, 0.75 mg Methylprednisolone, 4 mg These dose relationships apply only to oral or intravenous administration of these compounds. When these substances or their derivatives are injected intramuscularly or into joint spaces, their relative properties may be greatly altered.
In acute, self-limited allergic disorders or acute exacerbations of chronic allergic disorders, the following dosage schedule combining parenteral and oral therapy is suggested: Dexamethasone sodium phosphate injection, 4 mg per mL First Day 1 mL or 2 mL, intramuscularly Dexamethasone tablets, 0.75 mg Second Day 4 tablets in two divided doses Third Day 4 tablets in two divided doses Fourth Day 2 tablets in two divided doses Fifth Day 1 tablet Sixth Day 1 tablet Seventh Day No treatment Eighth Day Follow-up visit This schedule is designed to ensure adequate therapy during acute episodes, while minimizing the risk of overdosage in chronic cases.
In cerebral edema , dexamethasone sodium phosphate injection is generally administered initially in a dosage of 10 mg intravenously followed by 4 mg every six hours intramuscularly until the symptoms of cerebral edema subside. Response is usually noted within 12 hours to 24 hours and dosage may be reduced after two to four days and gradually discontinued over a period of five to seven days. For palliative management of patients with recurrent or inoperable brain tumors, maintenance therapy with either dexamethasone sodium phosphate injection or dexamethasone tablets in a dosage of 2 mg two or three times daily may be effective.
Dexamethasone Suppression Tests 1. Tests for Cushing's syndrome Give 1 mg of dexamethasone orally at 11:00 p.m. Blood is drawn for plasma cortisol determination at 8:00 a.m. the following morning.
For greater accuracy, give 0.5 mg of dexamethasone orally every 6 hours for 48 hours. Twenty‑four-hour urine collections are made for determination of 17-hydroxycorticosteroid excretion. 2.
Test to distinguish Cushing's syndrome due to pituitary ACTH excess from Cushing's syndrome due to other causes. Give 2 mg of dexamet…
⛔ Contraindications ▾
CONTRAINDICATIONS Systemic fungal infections (see WARNINGS , Fungal infections ). Dexamethasone tablets are contraindicated in patients who are hypersensitive to any components of this product.
⚠️ Warnings ▾
WARNINGS General Rare instances of anaphylactoid reactions have occurred in patients receiving corticosteroid therapy (see ADVERSE REACTIONS ). Increased dosage of rapidly acting corticosteroids is indicated in patients on corticosteroid therapy subjected to any unusual stress before, during, and after the stressful situation. Cardio-renal Average and large doses of corticosteroids can cause elevation of blood pressure, sodium and water retention, and increased excretion of potassium.
These effects are less likely to occur with the synthetic derivatives except when used in large doses. Dietary salt restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion.
Literature reports suggest an apparent association between use of corticosteroids and left ventricular free wall rupture after a recent myocardial infarction; therefore, therapy with corticosteroids should be used with great caution in these patients. Endocrine Corticosteroids can produce reversible hypothalamic-pituitary adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment. Adrenocortical insufficiency may result from too rapid withdrawal of corticosteroids and may be minimized by gradual reduction of dosage.
This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted. If the patient is receiving steroids already, dosage may have to be increased. Metabolic clearance of corticosteroids is decreased in hypothyroid patients and increased in hyperthyroid patients.
Changes in thyroid status of the patient may necessitate adjustment in dosage. Infections General Patients who are on corticosteroids are more susceptible to infections than are healthy individuals. There may be decreased resistance and inability to localize infection when corticosteroids are used.
Infection with any pathogen (viral, bacterial, fungal, protozoan or helminthic) in any location of the body may be associated with the use of corticosteroids alone or in combination with other immunosuppressive agents. These infections may be mild to severe. With increasing doses of corticosteroids, the rate of occurrence of infectious complications increases.
Corticosteroids may also mask some signs of current infection. Fungal Infections Corticosteroids may exacerbate systemic fungal infections and therefore should not be used in the presence of such infections unless they are needed to control life-threatening drug reactions. There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure (see PRECAUTIONS , Drug Interactions , Amphotericin B injection and potassium-depleting agents ).
Special Pathogens Latent disease may be activated or there may be an exacerbation of intercurrent infections due to pathogens, including those caused by Amoeba , Candida , Cryptococcus , Mycobacterium , Nocardia , Pneumocystis , Toxoplasma . It is recommended that latent amebiasis or active amebiasis be ruled out before initiating corticosteroid therapy in any patient who has spent time in the tropics or any patient with unexplained diarrhea. Similarly, corticosteroids should be used with great care in patients with known or suspected Strongyloides (threadworm) infestation.
In such patients, corticosteroid-induced immunosuppression may lead to Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia. Corticosteroids should not be used in cerebral malaria. Tuberculosis The use of corticosteroids in active tuberculosis should be restricted to those cases of fulminating or disseminated tuberculosis in which the corticosteroid is used for the management of the disease in conjunction with an a…
🤒 Adverse Reactions ▾
ADVERSE REACTIONS (listed alphabetically, under each subsection) The following adverse reactions have been reported with dexamethasone or other corticosteroids: Allergic Reactions: Anaphylactoid reaction, anaphylaxis, angioedema. Cardiovascular: Bradycardia, cardiac arrest, cardiac arrhythmias, cardiac enlargement, circulatory collapse, congestive heart failure, fat embolism, hypertension, hypertrophic cardiomyopathy in premature infants, myocardial rupture following recent myocardial infarction (see WARNINGS, Cardio-renal ), edema, pulmonary edema, syncope, tachycardia, thromboembolism, thrombophlebitis, vasculitis.
Dermatologic: Acne, allergic dermatitis, dry scaly skin, ecchymoses and petechiae, erythema, impaired wound healing, increased sweating, rash, striae, suppression of reactions to skin tests, thin fragile skin, thinning scalp hair, urticaria. Endocrine: Decreased carbohydrate and glucose tolerance, development of cushingoid state, hyperglycemia, glycosuria, hirsutism, hypertrichosis, increased requirements for insulin or oral hypoglycemic agents in diabetes, manifestations of latent diabetes mellitus, menstrual irregularities, secondary adrenocortical and pituitary unresponsiveness (particularly in times of stress, as in trauma, surgery, or illness), suppression of growth in pediatric patients.
Fluid and Electrolyte Disturbances: Congestive heart failure in susceptible patients, fluid retention, hypokalemic alkalosis, potassium loss, sodium retention, tumor lysis syndrome. Gastrointestinal: Abdominal distention, elevation in serum liver enzyme levels (usually reversible upon discontinuation), hepatomegaly, increased appetite, nausea, pancreatitis, peptic ulcer with possible perforation and hemorrhage, perforation of the small and large intestine (particularly in patients with inflammatory bowel disease), ulcerative esophagitis.
Metabolic: Negative nitrogen balance due to protein catabolism. Musculoskeletal: Aseptic necrosis of femoral and humeral heads, loss of muscle mass, muscle weakness, osteoporosis, pathologic fracture of long bones, steroid myopathy, tendon rupture, vertebral compression fractures. Neurological/Psychiatric: Convulsions, depression, emotional instability, euphoria, headache, increased intracranial pressure with papilledema (pseudotumor cerebri) usually following discontinuation of treatment, insomnia, mood swings, neuritis, neuropathy, paresthesia, personality changes, psychic disorders, vertigo.
Ophthalmic: Exophthalmos, glaucoma, increased intraocular pressure, posterior subcapsular cataracts, vision blurred. Other: Abnormal fat deposits, decreased resistance to infection, hiccups, increased or decreased motility and number of spermatozoa, malaise, moon face, weight gain. To report SUSPECTED ADVERSE REACTIONS, contact Bionpharma Inc. at 1-888-235-BION or 1-888-235-2466 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
🆘 Overdosage ▾
OVERDOSAGE Treatment of overdosage is by supportive and symptomatic therapy. In the case of acute overdosage, according to the patient’s condition, supportive therapy may include gastric lavage or emesis.
🧬 Clinical Pharmacology ▾
CLINICAL PHARMACOLOGY Glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. Glucocorticoids cause varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli.
Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have sodium-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs including dexamethasone are primarily used for their anti-inflammatory effects in disorders of many organ systems. At equipotent anti-inflammatory doses, dexamethasone almost completely lacks the sodium‑retaining property of hydrocortisone and closely related derivatives of hydrocortisone.
📦 How Supplied / Storage and Handling ▾
HOW SUPPLIED Dexamethasone tablets, USP are available as follows: 4 mg: Pale yellow, round tablets with side notches, a functional score on one side and debossed ‘ S2 ’ on the other side of the tablet. NDC 68788-8824-6 Bottles of 6. NDC 68788-8824-1 Bottles of 12.
NDC 68788-8824-5 Bottles of 15. NDC 68788-8824-3 Bottles of 30. Storage Store at 20°C to 25°C (68°F to 77°F) [See USP controlled room temperature].
Protect from moisture. Dispense in a tight, light-resistant, child-resistant container as defined in the USP/NF. Distributed by: Bionpharma Inc.
Princeton, NJ 08540 MADE IN INDIA Revised: 5/2023 FDA-04 2040008687 Repackaged By Preferred Pharmaceuticals Inc.
📋 Description ▾
DESCRIPTION Dexamethasone tablets, USP, for oral administration, are supplied as 4 mg, and 6 mg. Inactive ingredients are corn starch, D&C yellow 10 (4 mg), FD&C blue 1 (6 mg), lactose monohydrate, and magnesium stearate. The molecular weight for dexamethasone is 392.5 g/mol.
It is designated chemically as 9-fluoro-11β,17,21-trihydroxy-16α-methylpregna-1,4-diene-3,20-dione. The molecular formula is C 22 H 29 FO 5 and the structural formula is: Dexamethasone, USP a synthetic adrenocortical steroid, is a white to almost-white, crystalline powder. It is stable in air.
It is practically insoluble in water, very slightly soluble in ether, slightly soluble in methylene chloride and chloroform, and sparingly soluble in methanol, ethanol (96 %), acetone and 1,4 dioxane. image description